香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Jenscare Scientific Co., Ltd. 寧波健世科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：9877） 自願公告 香港聯合交易所有限公司證券上市規則第18A.05條 規 定 的 警 告 聲 明：概不保證 本公司將最終成功將機器人輔助經導管三尖瓣置換(TTVR)系 統 推 向 市 場 及╱ 或 商 業 化。本 公 司 股 東 及 潛 在 投 資 者 在 買 賣 本 公 司 股 份 時 請 審 慎 行 事。 本公告乃由寧波健世科技股份有限公司（「本公司」，連 同 其 附 屬 公 司，統 稱「本 集 團」）按 自 願 基 準 作 出，以 向 本 公 司 股 東 及 潛 在 投 資 者 提 供 有 關 本 集 團 最 新 業 務 及 產 品 開 發 的 最 新 資 ...

Jenscare Scientific Co., Ltd. 寧波健世科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：9877） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 茲 提 述 日 期 為 二 零 二 二 年 九 月 二 十 三 日 之 招 股 章 程，內 容 有 關（其 中 包 括）委 任李先生及黃偉超先生（「黃先生」）為 本 公 司 聯 席 公 司 秘 書，以 及 聯 交 所 就 李 先 生於本公司上市日期起三年期間（即 二 零 二 二 年 十 月 十 日 至 二 零 二 五 年 十 月 九 日）擔任其中一名聯席公司秘書的資格向本公司授出毋須嚴格遵守上市規則第 3.28條及第8.17條 規 定 的 豁 免。 本 公 司 謹 此 宣 布，聯 交 所 已 確 認 李 先 生 已 符 合 上 市 規 則 第3.28條所規 ...

Financial Performance - The company reported a total revenue of RMB 90.6 million for the year ending December 31, 2025, with other income and gains amounting to RMB 16.6 million, totaling RMB 107.2 million[3]. - The adjusted loss for the year, excluding share-based payment expenses and foreign exchange fluctuations, was RMB 162.4 million, a decrease of 11.3% compared to RMB 183.0 million in the previous year[4]. - The net cash flow used in operating activities was RMB 75.0 million, a significant decline of 65.5% from RMB 217.6 million in the previous year[4]. - The net loss for the year was RMB 272,704 thousand, compared to a loss of RMB 185,829 thousand in the previous year[18]. - The company reported a net loss attributable to equity holders of the parent of RMB 271,229,000 for the year ended December 31, 2025, compared to a loss of RMB 177,510,000 in 2024, representing an increase in loss of approximately 53%[19]. - The basic and diluted loss per share for the year was RMB 0.64, compared to RMB 0.43 in the previous year, indicating a worsening of the loss per share by approximately 49%[19]. - The group reported a pre-tax loss of RMB 78,762,000 for 2025, compared to RMB 70,318,000 in 2024[34]. - Research and development expenses increased to RMB 183,609,000 in 2025, up from RMB 142,637,000 in 2024[34]. - The financing cost increased from RMB 289,000 as of December 31, 2024, to RMB 867,000 during the reporting period, primarily due to rising interest rates on bank and other loans[93]. - The adjusted net loss under non-IFRS measures for 2025 is RMB 162.4 million, compared to RMB 183.0 million for 2024[96]. Product Development and Commercialization - The company is focusing on the commercialization of structural heart disease intervention products, with a strong emphasis on international expansion and the transformation of core technological achievements into market value[5]. - The LuX-Valve Plus product has accelerated its global clinical registration process, with successful FDA IDE approval for pivotal trials in the U.S. and ongoing CE certification in Europe[6]. - Ken-Valve has established a comprehensive sales network across hundreds of hospitals in China, achieving rapid sales and implantation growth in its first year of commercialization[9]. - The company aims to maintain its leading advantage in the tricuspid valve intervention field and advance the commercialization of core products in various regions[8]. - Ken-Valve successfully entered the overseas mature market after receiving approval from New Zealand's Medsafe in February 2026, marking a key breakthrough in its globalization strategy[10]. - The company is focused on continuous innovation and R&D to optimize its core product matrix, enhancing operational efficiency for global development[16]. - The company is focused on developing products for structural heart disease interventions, with a commitment to international expansion and a diverse product pipeline[44]. - The company has multiple products at various stages of commercialization and development, including those approved in China and New Zealand[45]. - The company has submitted applications for regulatory approvals, including CE certification and registration with the National Medical Products Administration in China[45]. - The company has established a comprehensive regional distribution network for the Ken-Valve product line, covering procurement platforms in 30 provinces in China[76]. Clinical Studies and Results - The TRINITY clinical study results, demonstrating the safety and efficacy of LuX-Valve Plus, will be presented at major international conferences, further supporting the company's position in the tricuspid valve replacement therapy field[7]. - Clinical data from JensClip demonstrated significant improvements in safety and efficacy, gaining widespread attention from global clinical experts[14]. - The TRINITY study included 161 patients across 20 global centers, demonstrating positive safety and clinical performance for LuX-Valve Plus in high-risk patients[53]. - The TRINITY study's 6-month follow-up results indicate a composite adverse event rate of 19.9% and 94.4% of patients showing no moderate or severe regurgitation[55]. - In the TRINITY study, over 75% of patients used valve sizes of 55mm to 70mm, with a significant improvement in heart function and quality of life observed[56]. - Ken-Valve has achieved a 97.18% device success rate with an average operation time of 8.70 minutes, and a one-year all-cause mortality rate of only 5.63%[61]. - JensClip's clinical study showed a device operation success rate of approximately 95% and an all-cause mortality rate of only 1.8% after one year of follow-up[66]. Financial Position and Assets - Total non-current assets decreased to RMB 275,623,000 in 2025 from RMB 341,710,000 in 2024, reflecting a decline of about 19%[20]. - Current assets also decreased to RMB 620,609,000 in 2025 from RMB 685,855,000 in 2024, a reduction of approximately 9.5%[20]. - The company's total liabilities increased, with current liabilities rising to RMB 105,871,000 in 2025 from RMB 64,201,000 in 2024, an increase of about 65%[20]. - The company's total equity decreased to RMB 773,126,000 in 2025 from RMB 916,953,000 in 2024, a decline of approximately 16%[21]. - The company reported an increase in trade payables to RMB 25,150,000 in 2025 from RMB 12,097,000 in 2024, which is an increase of about 108%[20]. - Cash and cash equivalents decreased by 16.3% from RMB 606.0 million as of December 31, 2024, to RMB 507.4 million as of December 31, 2025[98]. - The current ratio decreased from 10.7 in 2024 to 5.9 in 2025, while the debt-to-asset ratio increased from 10.8% to 13.7%[101]. - The total amount of bank and other borrowings decreased from RMB 60.3 million as of December 31, 2024, to RMB 43.8 million as of December 31, 2025[101]. Governance and Compliance - The company has adopted the corporate governance code and has complied with all applicable provisions, except for a specific deviation regarding the roles of the chairman and CEO[118][119]. - The chairman and CEO roles were separated on January 15, 2025, to enhance corporate governance compliance[120]. - The audit committee, consisting of three independent non-executive directors, has reviewed the annual performance and confirmed compliance with applicable accounting standards[124][125]. - The company has received confirmation from all directors regarding compliance with the standard code of conduct for securities trading during the reporting period[122]. Employee and Shareholder Matters - The company has established a performance evaluation mechanism to assess employee performance, which influences salary adjustments and career development planning[109]. - The company adopted an employee incentive plan on October 30, 2020, and an H-share plan on December 15, 2023[110]. - The board of directors does not recommend the payment of a final dividend for the reporting period[114]. - The annual general meeting is scheduled for May 28, 2026, with a suspension of share transfer registration from May 22 to May 28, 2026[116][117].

寧波健世科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：9877） 董事會會議通告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Jenscare Scientific Co., Ltd. 寧波健世科技股份有限公司（「本公司」連同其附屬公司（「本集團」）董 事（「董 事」） 會（「董事會」）謹 此 宣 佈，董 事 會 會 議 將 於 二 零 二 六 年 三 月 二 十 六 日（星 期 四）舉 行，藉 以（其 中 包 括）考慮及批准本集團截至二零二五年十二月三十一日止之年 度 業 績 及 其 發 佈，並 考 慮 建 議 派 發 末 期 股 息（如 有）及 處 理 任 何 其 他 事 務。 承董事會命 寧波健世科技股份有限公司 執行董事兼首席執行官 潘斐先生 香 港，二 零 二 六 年 三 月 十 六 日 於 本 公 告 日 期， ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 寧波健世科技股份有限公司 呈交日期: 2026年3月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09877 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 310,306,209 | RMB | | 1 RMB | | 310,306,209 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 310,306,209 | RMB | | 1 RMB | | 310,306,209 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請 ...

Core Viewpoint - The company, Jian Shi Technology-B (09877), has received registration approval from the New Zealand Medicines and Medical Devices Safety Authority for its transcatheter aortic valve replacement system Ken-Valve and transcatheter tricuspid valve replacement system LuX-ValvePlus, which will accelerate the global commercialization of its product portfolio [1][5]. Group 1 - Jian Shi Technology-B's stock price initially rose over 8% in the morning but later adjusted to a slight increase of 0.24%, trading at HKD 8.50 with a transaction volume of HKD 3.4321 million [1][5]. - The company is actively promoting the commercialization of Ken-Valve and LuX-ValvePlus in New Zealand following their recent registration approval [1][5]. - The announcement highlights that the products have gained broad market recognition due to their design advantages, ongoing clinical trials, and continuous therapy promotion efforts [1][5].

Group 1 - The core viewpoint of the article highlights that KenSheng Technology-B (09877) has seen a significant stock increase of over 8%, reaching 9.2 HKD with a trading volume of 1.0444 million HKD [1] - The company announced that its transcatheter aortic valve replacement system, Ken-Valve, and transcatheter tricuspid valve replacement system, LuX-ValvePlus, have recently received registration approval from the New Zealand Medicines and Medical Devices Safety Authority [1] - The approval is expected to accelerate the global commercialization process of these two key products, aligning with the company's long-term strategic goals [1] Group 2 - The announcement emphasizes that the products have gained widespread market recognition due to their design advantages, ongoing clinical trials, and continuous promotion of therapies [1] - The company is actively pushing for the commercialization of Ken-Valve and LuX-ValvePlus in New Zealand following the recent regulatory approval [1]

Core Viewpoint - The company, Kenji Technology-B (09877), has seen its stock price increase by over 8% following the announcement of regulatory approvals for its medical devices in New Zealand [1] Group 1: Product Approval - Kenji Technology has received registration approval from the New Zealand Medicines and Medical Devices Safety Authority for its transcatheter aortic valve replacement system, Ken-Valve, and its transcatheter tricuspid valve replacement system, LuX-ValvePlus [1] - The company is actively promoting the commercialization of these two products in New Zealand [1] Group 2: Market Recognition - The products, Ken-Valve and LuX-ValvePlus, have gained widespread market recognition due to their design advantages, ongoing clinical trials, and continuous therapy promotion efforts [1] Group 3: Strategic Goals - With the approval of these significant products, the company aims to accelerate the global commercialization process of its product portfolio to further achieve its long-term strategic goals [1]

Core Viewpoint - The company,健世科技-B (09877), has seen its stock price increase by over 8% following the announcement of regulatory approvals for its medical devices in New Zealand [1] Group 1: Product Approvals - The company announced that its Ken-Valve transcatheter aortic valve replacement system and LuX-ValvePlus transcatheter tricuspid valve replacement system have received registration approval from the New Zealand Medicines and Medical Devices Safety Authority [1] - The approval is expected to accelerate the commercialization of these products in New Zealand [1] Group 2: Market Recognition - The company highlighted that the Ken-Valve and LuX-ValvePlus have gained widespread market recognition due to their design advantages, ongoing clinical trials, and continuous promotion of therapies [1] - This recognition is seen as a positive factor in the company's strategy to enhance its global commercialization efforts [1] Group 3: Strategic Goals - The company aims to further its long-term strategic goals by expediting the global commercialization process of its product portfolio following the recent approvals [1]

Core Viewpoint - The company has received regulatory approval for its Ken-Valve and LuX-ValvePlus products from the New Zealand Medicines and Medical Devices Safety Authority, which will accelerate the global commercialization of its product portfolio [1] Group 1: Product Approval - The Ken-Valve and LuX-ValvePlus systems have recently obtained registration approval in New Zealand [1] - The approval is expected to enhance the company's market presence and facilitate the commercialization of these products [1] Group 2: Market Recognition - The products have gained widespread recognition in the market due to their design advantages and ongoing clinical trials [1] - Continuous promotion of the therapies has contributed to the positive reception of the products [1] Group 3: Strategic Goals - The company aims to expedite the global commercialization process of its product lineup to achieve its long-term strategic objectives [1]